Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial crawled time : 13:20 save search
Geneos Therapeutics Announces Eight of 34 Patients to Achieve Complete Response, Complete Molecular Response
Published: 2023-08-22 (Crawled : 13:20) - biospace.com/
PSNL | $1.265 -1.94% -1.98% 200K
|
Health Technology
|
| O: 1.69%
H: 0.56%
C: -1.67%
therapeutics response molecular
Anebulo Receives Positive Feedback from FDA on Path to Advance Phase 3 Clinical Development of ANEB-001 and Completes Dosing of Phase 2 Extension
Published: 2023-08-21 (Crawled : 13:20) - biospace.com/
ANEB | $2.78 -7.14% 1.5K
|
Manufacturing
|
| O: 7.5%
H: 12.62%
C: 2.66%
aneb-001 fda positive extension
Elevation Oncology Announces First Patient Dosed in the Phase 1 Clinical Trial Evaluating EO-3021
Published: 2023-08-16 (Crawled : 13:20) - biospace.com/
ELEV | $4.05 6.58% 6.17% 490K
|
Professional, Scientific, and T...
|
| O: -0.11%
H: 1.1%
C: -5.0%
eo-3021 trial
Novocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer
Published: 2023-07-21 (Crawled : 13:20) - biospace.com/
NVCR | $11.82 -2.23% -2.28% 810K
|
Health Technology
|
| O: -0.75%
H: 2.79%
C: 1.59%
favorable cancer pancreatic tumor trial therapy
GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia
Published: 2023-07-20 (Crawled : 13:20) - globenewswire.com
GOVX | $1.54 2.67% 2.6% 30K
|
Health Technology
|
| O: 0.18%
H: 1.98%
C: -0.28%
covid-19 vaccine leukemia trial phase 2
Atossa Therapeutics Receives Approval from Health Canada to Conduct Phase 2 EVANGELINE Clinical Trial in Canada
Published: 2023-07-20 (Crawled : 13:20) - globenewswire.com
ATOS | $1.415 3.28% 3.18% 1M
|
Health Technology
|
| O: 4.67%
H: 2.68%
C: 1.79%
health approval canada trial therapeutics phase 2
Panacea Life Sciences Holdings, Inc. Announces CBD/CBG Clinical Trial Findings for the Management of Irritable Bowel Symptoms
Published: 2023-07-20 (Crawled : 13:20) - globenewswire.com
PLSH | $0.1284 -35.6% 16K
|
n/a
|
| O: -21.26%
H: 6.67%
C: 0.0%
management life sciences trial
Immix Biopharma Reports 2nd Positive Interim Clinical Trial Data Readout in Relapsed/Refractory Metastatic Colorectal Cancer in Ongoing Phase 1b/2a IMX-110 IMMINENT-01 Clinical Trial
Published: 2023-07-17 (Crawled : 13:20) - globenewswire.com
IMMX | $2.19 0.0% 190K
|
|
| O: -3.49%
H: 22.62%
C: -2.71%
imx-110 readout positive cancer biopharma ongoing trial
Lyndra Therapeutics Announces Leadership Changes, Update on Pivotal Trial Progress
Published: 2023-07-17 (Crawled : 13:20) - biospace.com/
FNCTF | News | $11.0354 -20.84% 320
|
Communications
|
| O: 4.62%
H: 0.0%
C: -1.54%
GILD | $66.95 0.29% 0.28% 5.6M
|
Health Technology
|
| O: -0.67%
H: 1.42%
C: 1.06%
update trial therapeutics
Atossa Therapeutics Provides Enrollment Update for Ongoing Phase 2 Karisma-Endoxifen Clinical Trial
Published: 2023-07-10 (Crawled : 13:20) - globenewswire.com
ATOS | $1.415 3.28% 3.18% 1M
|
Health Technology
|
| O: 0.0%
H: 2.48%
C: 0.84%
update ongoing trial therapeutics phase 2
Atossa Therapeutics and Quantum Leap Healthcare Provide Enrollment Update for (Z)-Endoxifen Arm of Ongoing I-SPY 2 Clinical Trial
Published: 2023-06-28 (Crawled : 13:20) - globenewswire.com
ATOS | $1.415 3.28% 3.18% 1M
|
Health Technology
|
| O: 2.62%
H: 24.49%
C: 19.39%
quantum arm leap update ongoing trial therapeutics
Immix Biopharma Subsidiary Nexcella Completes Pre-IND Meeting with FDA on NXC-201 US Clinical Trial
Published: 2023-06-26 (Crawled : 13:20) - globenewswire.com
IMMX | $2.19 0.0% 190K
|
|
| O: -2.3%
H: 1.96%
C: -4.71%
nxc-201 fda biopharma meeting trial
Sorrento Announces the Full Enrollment of the Pivotal Phase 3 Trial with Olgotrelvir (OVYDSOTM) (STI-1558), a Second Generation Oral Mpro Inhibitor, as a Standalone Treatment for COVID-19
Published: 2023-06-26 (Crawled : 13:20) - globenewswire.com
SRNE | $0.02 -8.85% 200K
|
Health Technology
|
| O: 3.9%
H: 0.0%
C: -3.06%
sti-1558 covid-19 treatment trial
Oncolytics Biotech's® Pelareorep Selected for Inclusion in Precision PromiseSM Pivotal Phase 3 Platform Trial
Published: 2023-06-22 (Crawled : 13:20) - biospace.com/
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 2.78%
H: 28.38%
C: 13.51%
trial platform
Atossa Completes Enrollment of Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer
Published: 2023-06-12 (Crawled : 13:20) - globenewswire.com
ATOS | $1.415 3.28% 3.18% 1M
|
Health Technology
|
| O: 1.06%
H: 5.73%
C: 3.81%
breast cancer treatment her2- trial
Annovis Bio Announces Completion of Phase III Parkinson's Disease Treatment Enrollment at Record Pace
Published: 2023-06-08 (Crawled : 13:20) - biospace.com/
ANVS | $11.49 14.22% 0.0% 320K
|
Health Technology
|
| O: 8.73%
H: 0.0%
C: -9.01%
disease parkinson's treatment
Baudax Bio Announces Additional, Positive Top-Line Results From Phase 2 Randomized Clinical Trial of BX1000
Published: 2023-06-07 (Crawled : 13:20) - globenewswire.com
BXRX | $0.1864 -54.35% 330K
|
Health Technology
|
| O: 7.16%
H: 5.23%
C: -2.57%
bx1000 positive trial results phase 2
Ocular Therapeutix™ Completes Enrollment of the HELIOS Clinical Trial of OTX-TKI for the Treatment of Diabetic Retinopathy Interim 6-month Data Expected in the First Quarter of 2024
Published: 2023-06-07 (Crawled : 13:20) - biospace.com/
OCUL | News | $5.075 -2.78% -2.86% 3.7M
|
Health Technology
|
| O: 0.39%
H: 0.91%
C: -3.39%
ocular expected treatment trial diabetic
Morphogenesis, Inc. and CohBar, Inc. Announce Positive Results from Phase 1b Trial of IFx-Hu2.0
Published: 2023-06-05 (Crawled : 13:20) - biospace.com/
CWBR | $0.9003 -11.88% 360
|
Health Technology
|
| O: 6.64%
H: 8.85%
C: -11.48%
positive trial results
TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the 2023 Consortium of Multiple Sclerosis Centers Annual Meeting
Published: 2023-06-02 (Crawled : 13:20) - globenewswire.com
TGTX | $14.12 2.47% 2.41% 2.3M
|
Health Technology
|
| O: 0.67%
H: 0.54%
C: -3.77%
briumvi presentation sclerosis trials meeting therapeutics
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.